Paradigm Biopharmaceuticals’ Phase 2 clinical trial is a success…so far

Nick Sundich Nick Sundich, October 4, 2022

One of the best pieces of news shareholders in a biotech stock can receive is successful Phase II clinical trial results and Paradigm Biopharmaceuticals (ASX: PAR) has delivered that this morning. Shareholders appear to have embraced the results, although they are only interim and there is some way to go before Paradigm Biopharmaceuticals gets regulatory approval for its drug.

 

Another small step for Paradigm Biopharmaceuticals

Paradigm Biopharmaceuticals was founded to repurpose pentosan polysulphate sodium, or PPS for short. It eventually settled on osteoartritis (OA), hoping that injecting PPS could reduce the pain. And OA is a big market with over 300m global cases in knee and hip OA alone.

Today’s study was not the first set of positive data and only interim – the study will go for 12 months but the data was from Day 56. Nevertheless, it was positive news.

PPS treatment showed statistically significant improvements in pain, function, stiffness and WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) scores. 73% achieved a reduction in pain of 30% or greater while 60% achieved an improvement of 50% of greater.

 

More important milestones coming

But Paradigm Biopharmaceuticals has bigger ambitions. It is going for FDA approval for OA and is undertaking two Phase III clinical programs with that end goal in mind.

Approval is ultimately up to the FDA and only stands a chance if the results pass Phase III. But the fact that PPS has passed multiple earlier studies and obtained FDA Fast Track Approval helps its cause.

 

 

 

What are the Best ASX Stocks to invest in right now?

Check our ASX stock buy/sell tips

 

Blog Categories

Get Our Top 5 ASX Stocks for FY26

Recent Posts

TPG

Why TPG’s $651M Bid for Infomedia Could Backfire

What does it say about a company when one of the world’s biggest private equity firms offers a 30 percent…

Shopify

Shopify Jumps 100% — Can Its Q2 Momentum Hold in H2

What if the real winner of the AI and e-commerce boom isn’t a retailer, but the platform quietly powering their…

What if the future of global clean energy hinges on a remote hillside in Malawi

What if the future of global clean energy hinges on a remote hillside in Malawi?

As governments race to secure rare earths, the essential ingredients in electric vehicles, wind turbines, and military tech, investors are…